This brings into question if HER2-low should represent a separate subtype of BC distinct from HER2-zero (IHC score 0) tumours, as this would have wide-ranging implications from HER2 testing algorithms to clinical trial design. This evidence concerns the gene ERBB2 and neoplasm.